The increase in MDSC and inflammatory factors associated with EGFR TKI treatment has been proposed to explain why most EGFR TKI-resistant NSCLC patients are also refractory to anti-PD-1/PD-L1 ICIs (79). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.